Data from the upcoming Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) trial [15], which enrolled a large proportion of participants without prevalent cardiovascular disease, will provide additional information regarding the extent to which SGLT2 inhibitors reduce cardiovascular events in this group of individuals with type 2 diabetes
Experiment with your meal timing to see how it affects your energy and appetite
Your provider monitors your progress monthly, adjusts your dose based on appetite, side effects, and weight loss trends, and coordinates with any existing healthcare providers
[DOI] [PMC free article] [PubMed] [Google Scholar] Dupuy P
Inclusion of tumor targeting ligands demonstrated specific delivery of high payload chemotherapeutics to tumors, controlled release of chemical drugs and strong tumor inhibition
2021 May 6;384(18):1719-1730 5